EICHORCondition: Metastatic Castration-Sensitive Prostate Cancer · Sponsor: AstraZeneca
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Research Site | Chandler, Arizona, United States | — |
| Research Site | Gilbert, Arizona, United States | — |
| Research Site | Phoenix, Arizona, United States | — |
| Research Site | Tucson, Arizona, United States | — |
| Research Site | Little Rock, Arkansas, United States | — |
| Research Site | Springdale, Arkansas, United States | — |
| Research Site | Bakersfield, California, United States | — |
| Research Site | Fountain Valley, California, United States | — |
| Research Site | Fullerton, California, United States | — |
| Research Site | Los Angeles, California, United States | — |
| Research Site | Montebello, California, United States | — |
| Research Site | San Francisco, California, United States | — |
+ 310 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06120491